Risikostratifizierung mit unterschiedlichen Score-Systemen

Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 105: 310–315

Böger GI, Hoopmann M, Busse R et al. (2003) Arzneimittelverordnungen bei koronarer Herzkrankheit: Werden die Therapieempfehlungen beachtet? Z Kardiol 92: 466–475

Bruckenberger E (2001) Herzbericht 2000 mit Transplantationschirurgie; 13. Bericht des Krankenhausausschusses der Arbeitsgemeinschaft der obersten Landesgesundheitsbehörden der Länder 2000 mit Transplantationschirurgie. Hannover, S 153

Conroy RM, Pyörälä K, Fitzgerald AP et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987–1003

EUROASPIRE II Study Group (2001) Life style and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal Results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22: 554–572

Ezzati M, Vander Hoorn S, Rodgers A et al. (2003) Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 362: 271–280

Gohlke H, Kübler W, Mathes P et al. (2003) Positionspapier zur Primärprävention kardiovaskulärer Erkrankungen. Z Kardiol 92: 522–524

Gotto AM, for the AFCAPS/TexCAPS Research Group (1998) Primary prevention of acute Coronary events mith Lovastatin in men and women with average Cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279: 1615–1622

Heidrich J, Wellmann J, Hense HW et al. (2003) Klassische Risikofaktoren für Herzinfarkt und Gesamtsterblichkeit in der Bevölkerung. 13-Jahres-Follow-up der MONICA Augsburg-Kohortenstudie. Z Kardiol 92: 445–454

Hense HW, Schulte H, Löwel H et al. (2003) Framingham risk function overestimates risk of coronary heart disease in men and women from Germany. Results from the MONICA Augsburg cohort and the PROCAM cohorts. Eur Heart J 24: 937–945

Johannesson M (2001) At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 22: 919–925

Keil U, Fitzgerald AP, Gohlke H et al. (2005) Risikoabschätzung tödlicher Herz-Kreislauferkrankungen- Die neuen SCORE-Deutschland-Tabellen für die Primärprävention Dtsch Arztebl 102: A 1808–1812

National Cholesterol Education Program (2001) Adult Treatment Panel III. JAMA 285: 2486–2495

Shepherd J, Cobbe SM, Ford I et al. (1996) West Of Scotland Coronary Prevention Study (WOSCOPS): Identification of high risk groups and comparison with other cardiovascular Intervention trials. Lancet 348: 1339–1342

Stamler J, Stamler R, Neaton JD et al. (1999) Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282: 2012–2018

Tuomilehto J, Lindstrom J, Eriksson JG et al.(2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350

Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. Br Med J 326: 1419–1425

Wood D, De Backer G, Faergeman O et al. (1998) Prevention of coronary heart disease in clinical practice – recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19: 1434–1503

Wood D, De Backer G, Graham I et al. (2002) Kardiovaskuläres Risikomanagement – Richtlinien zur Prävention der koronaren Herzkrankheit. Science Press, London

Yusuf S, Hawken S, Ounpuu S et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 364: 937–952